A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
CRYO CELL INTERNATIONAL INC
CCEL
$28M
Mkt Cap
$3.46
-1.14%
CRYO CELL INTERNATIONAL INC (CCEL) has a 5-year average return on invested capital (ROIC) of 9.1%. This is below average and may indicate limited pricing power.
CRYO CELL INTERNATIONAL INC (CCEL) has a market capitalization of $28M. It is classified as a small-cap stock.
Yes, CRYO CELL INTERNATIONAL INC (CCEL) pays a dividend with a trailing twelve-month yield of 4.34%. The company also returns capital through share buybacks, with a buyback yield of 0.61%.
CRYO CELL INTERNATIONAL INC (CCEL) operates in the Services-Misc Health & Allied Services, Nec industry, within the Healthcare sector.
CRYO CELL INTERNATIONAL INC (CCEL) reported annual revenue of $32 million in its most recent fiscal year, based on SEC EDGAR filings.
CRYO CELL INTERNATIONAL INC (CCEL) has a net profit margin of -7.7%. The company is currently unprofitable.
CRYO CELL INTERNATIONAL INC (CCEL) generated $5 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Cryo-Cell International, Inc. (the “Company” or “Cryo-Cell”) is a Delaware corporation that was incorporated in 1989. The Company is organized in three reportable segments; 1.) cellular processing and cryogenic storage for family use, with a current focus on the collection and preservation of umbilical cord blood and tissue stem cells, 2.) the manufacture of PrepaCyte® CB Processing System (“PrepaCyte CB”) units, the processing technology used to process umbilical cord blood stem cells, and 3.) cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company, in combination with its global affiliates, currently stores over 250,000 cord blood and cord tissue specimens worldwide for the exclusive benefit of newborn babies and possibly other members of their families. Founded in 1989, the Company was the world’s first private cord blood bank to separate and store stem cells in 1992. The Company's U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 31M | 32M | 32M | 31M | 30M | 29M |
| Net Income | -2.7M | -2.4M | 402K | -9.5M | 2.8M | 2.1M |
| EPS | $-0.33 | $-0.30 | $0.05 | $-1.14 | $0.33 | $0.25 |
| Free Cash Flow | 4.9M | 5.2M | 3.6M | 2.1M | -3.6M | 6.1M |
| ROIC | 0.2% | 0.8% | 3.2% | -20.1% | 52.5% | 222.7% |
| Gross Margin | - | 76.6% | 75.2% | 73.2% | 71.0% | 68.9% |
| Debt/Equity | 0.00 | -0.52 | -0.74 | -0.91 | -6.33 | 1.34 |
| Dividends/Share | $0.15 | $0.40 | $0.25 | $0.90 | $0.90 | $0.00 |
| Operating Income | 192K | 482K | 3.5M | -12M | 4.0M | 4.0M |
| Operating Margin | 0.6% | 1.5% | 10.9% | -39.3% | 13.3% | 13.9% |
| ROE | 0.0% | - | - | - | - | 49.8% |
| Shares Outstanding | 8M | 8M | 8M | 8M | 8M | 8M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 20M | 21M | 23M | 25M | 29M | 32M | 31M | 29M | 30M | 31M | 32M | 32M | 31M |
| Gross Margin | 77.6% | 79.5% | 70.5% | 73.5% | 70.8% | 68.5% | 69.0% | 68.9% | 71.0% | 73.2% | 75.2% | 76.6% | N/A |
| R&D | 64K | 46K | 53K | 41K | 92K | 30K | 24K | 50K | 385K | 1.2M | 1.2M | 376K | 344K |
| SG&A | 12M | 12M | 15M | 13M | 16M | 15M | 14M | 15M | 16M | 17M | 19M | 18M | 19M |
| EBIT | 2.0M | 2.9M | 434K | 5.0M | 5.2M | 5.1M | 7.7M | 4.0M | 4.0M | -12M | 3.5M | 482K | 192K |
| Op. Margin | 9.8% | 13.9% | 1.9% | 19.7% | 17.8% | 15.9% | 24.6% | 13.9% | 13.3% | -39.3% | 10.9% | 1.5% | 0.6% |
| Net Income | 554K | 8.1M | -1.3M | 2.3M | -855K | 2.3M | 3.6M | 2.1M | 2.8M | -9.5M | 402K | -2.4M | -2.7M |
| Net Margin | 2.8% | 38.4% | -5.7% | 9.1% | -2.9% | 7.2% | 11.6% | 7.2% | 9.1% | -30.4% | 1.3% | -7.7% | -8.5% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 2.3M | 1.3M | 1.1M | 407K | 3.7M | 0 | 4.4M | 4.4M |
| Returns on Capital | |||||||||||||
| ROIC | 14.9% | 19.7% | 2.2% | 14.7% | 7.3% | N/M | 11.9% | N/M | 52.5% | -20.1% | 3.2% | 0.8% | 0.2% |
| ROE | -5.5% | -103.3% | 13.0% | -16.6% | N/A | N/A | N/A | 49.8% | N/A | N/A | N/A | N/A | 0.0% |
| ROA | 5.1% | 54.6% | -6.8% | 10.7% | -2.0% | 5.3% | 7.8% | 3.4% | 4.3% | -15.6% | 0.6% | -3.8% | -4.4% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 1.6M | 4.9M | 5.0M | 5.7M | 5.3M | 6.3M | 8.5M | 7.9M | 8.6M | 8.9M | 6.0M | 5.5M | 5.2M |
| Free Cash Flow | 1.4M | 4.7M | 4.6M | 5.6M | 4.9M | 5.6M | 8.4M | 6.1M | -3.6M | 2.1M | 3.6M | 5.2M | 4.9M |
| Owner Earnings | 979K | 4.2M | 3.1M | 4.6M | 4.5M | 5.5M | 7.5M | 6.6M | 6.6M | 6.7M | 4.5M | 4.1M | 3.9M |
| CapEx | 121K | 108K | 343K | 98K | 446K | 662K | 100K | 1.8M | 12M | 6.8M | 2.4M | 230K | 235K |
| Maint. CapEx | 171K | 92K | 155K | 132K | 317K | 401K | 372K | 1.0M | 1.5M | 1.4M | 694K | 985K | 981K |
| Growth CapEx | 0 | 16K | 188K | 0 | 129K | 261K | 0 | 795K | 11M | 5.4M | 1.7M | 0 | 0 |
| D&A | 171K | 92K | 155K | 132K | 317K | 401K | 372K | 1.0M | 1.5M | 1.4M | 694K | 985K | 981K |
| CapEx/OCF | 7.8% | 2.2% | 6.9% | 1.7% | 8.4% | 10.5% | 1.2% | 23.1% | 141.9% | 76.7% | 40.0% | 4.2% | 4.5% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.7M | 0 | 2.0M | 3.2M | 1.2M |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 15.0% | N/A | 4.0% | 7.2% | 4.3% |
| Share Buybacks | 2.7M | 3.2M | 11M | 447K | 447K | 992K | 992K | 249K | 1.8M | 799K | 1.4M | 170K | 170K |
| Buyback Yield | 10.8% | 11.9% | 37.5% | 0.9% | N/A | 1.9% | N/A | 0.3% | 5.2% | 2.1% | 2.1% | 0.5% | 0.6% |
| Stock-Based Comp | 404K | 603K | 1.8M | 972K | 478K | 398K | 622K | 302K | 461K | 817K | 781K | 417K | 278K |
| Debt Repayment | 0 | 0 | 379K | 0 | 169K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -1.1M | -2.2M | -699K | -3.3M | 709K | 7.7M | 2.0M | -2.7M | 7.9M | 9.0M | 6.3M | 6.3M | 5.2M |
| Cash & Equiv. | 3.3M | 4.2M | 3.5M | 6.3M | 6.0M | 6.5M | 10M | 8.3M | 1.7M | 406K | 561K | 319K | 2.9M |
| Long-Term Debt | 2.3M | 2.3M | 1.4M | 1.4M | 1.4M | 9.0M | 5.9M | 875K | 8.7M | 8.6M | 8.5M | 8.4M | 875K |
| Debt/Equity | -0.21 | -0.53 | -0.22 | -0.27 | -0.86 | -2.18 | -4.67 | 1.34 | -6.33 | -0.91 | -0.74 | -0.52 | 0.00 |
| Interest Coverage | 1.7 | 2.2 | 0.5 | 3.8 | 3.4 | 3.0 | 5.0 | 2.9 | 2.6 | -9.9 | 1.9 | 0.2 | 0.1 |
| Equity | -11M | -5.0M | -15M | -13M | -8.9M | -7.0M | -2.7M | 4.2M | -1.5M | -11M | -13M | -19M | -18M |
| Total Assets | 10M | 19M | 20M | 24M | 42M | 43M | 46M | 61M | 65M | 61M | 65M | 62M | 61M |
| Total Liabilities | 21M | 24M | 35M | 36M | 51M | 50M | 49M | 56M | 66M | 72M | 78M | 80M | 79M |
| Intangibles | 28K | 516K | 261K | 226K | 1.3M | 1.2M | 1.2M | 1.6M | 1.5M | 989K | 921K | 863K | 852K |
| Retained Earnings | -34M | -25M | -27M | -24M | -25M | -22M | -19M | -17M | -22M | -31M | -33M | -38M | -38M |
| Working Capital | -635K | -71K | -4.1M | -1.2M | -670K | -42K | 2.1M | -5.3M | -9.9M | -11M | -9.0M | -8.0M | -6.7M |
| Current Assets | 8.5M | 10M | 9.0M | 13M | 15M | 15M | 19M | 16M | 9.6M | 9.5M | 13M | 12M | 11M |
| Current Liabilities | 9.1M | 10M | 13M | 14M | 15M | 15M | 16M | 21M | 19M | 21M | 22M | 20M | 18M |
| Per Share Data | |||||||||||||
| EPS | 0.05 | 0.83 | -0.16 | 0.30 | -0.11 | 0.27 | 0.45 | 0.25 | 0.33 | -1.14 | 0.05 | -0.30 | -0.33 |
| Owner EPS | 0.09 | 0.43 | 0.37 | 0.60 | 0.58 | 0.65 | 0.93 | 0.79 | 0.79 | 0.80 | 0.56 | 0.50 | 0.49 |
| Book Value | -0.97 | -0.51 | -1.87 | -1.62 | -1.15 | -0.82 | -0.33 | 0.50 | -0.18 | -1.32 | -1.64 | -2.30 | -2.28 |
| Cash Flow/Share | 0.14 | 0.50 | 0.60 | 0.74 | 0.69 | 0.74 | 1.05 | 0.95 | 1.02 | 1.07 | 0.75 | 0.68 | -0.21 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.90 | 0.90 | 0.25 | 0.40 | 0.15 |
| Shares Out. | 11.1M | 9.8M | 8.3M | 7.7M | 7.8M | 8.5M | 8.1M | 8.3M | 8.4M | 8.4M | 8.0M | 8.1M | 8.1M |
| Valuation | |||||||||||||
| P/E Ratio | 44.6 | 3.3 | N/A | 21.4 | N/A | 23.0 | 13.4 | 39.6 | 12.6 | N/A | 171.0 | N/A | -10.5 |
| P/FCF | 17.2 | 5.7 | 6.2 | 8.8 | 9.1 | 9.4 | 5.8 | 13.5 | N/A | 18.2 | 19.1 | 6.6 | 5.6 |
| EV/EBIT | 11.9 | 8.6 | 69.4 | 9.6 | 8.7 | 10.4 | 5.9 | 19.6 | 10.4 | N/A | 21.1 | 82.3 | 172.8 |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 19.7 | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | 1.1 | 1.0 | 1.0 | 1.4 | 1.8 | 1.6 | 1.5 | 2.2 | 1.7 | 1.2 | 1.6 | 1.4 | 0.9 |
| FCF Yield | 5.8% | 17.5% | 16.1% | 11.3% | 11.0% | 10.7% | 17.2% | 7.4% | -10.3% | 5.5% | 5.2% | 15.1% | 17.7% |
| Market Cap | 25M | 27M | 29M | 50M | 45M | 53M | 49M | 82M | 35M | 38M | 69M | 35M | 28M |
| Avg. Price | 2.01 | 2.26 | 2.81 | 4.64 | 6.58 | 6.10 | 5.93 | 7.79 | 6.09 | 4.39 | 6.31 | 5.57 | 3.46 |
| Year-End Price | 2.23 | 2.77 | 3.49 | 6.42 | 5.74 | 6.21 | 6.02 | 9.89 | 4.15 | 4.53 | 8.55 | 4.30 | 3.46 |
CRYO CELL INTERNATIONAL INC passes 4 of 9 quality checks, suggesting mixed fundamentals.
On a free-cash-flow basis, the stock trades at 5.3x vs a median of 9.1x. The company's 5-year average ROIC is 9.1% with a gross margin of 73.0%. Total shareholder yield (dividends + buybacks) is 5.0%. At current prices, the estimated annualized return to fair value is -13.4%.
CRYO CELL INTERNATIONAL INC (CCEL) reported earnings per share (EPS) of $-0.30 in its most recent fiscal year.
CRYO CELL INTERNATIONAL INC (CCEL) has a 5-year average gross margin of 73.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for CRYO CELL INTERNATIONAL INC (CCEL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CRYO CELL INTERNATIONAL INC (CCEL) has a book value per share of $-2.30, based on its most recent annual SEC filing.